molecules

Synthesis, Molecular Structure and Reactivity of 5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines

Anita Kornicka [1], Franciszek Sączewski [1,*] and Maria Gdaniec [2]

[1] Department of Chemical Technology of Drugs, Medical University of Gdańsk, 107 Gen. J. Hallera Str., 80-416 Gdańsk, Poland.

[2] Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland

[*] Author to whom correspondence should be addressed. E-mail: saczew@sanus.amg.gda.pl; Tel. (+48)-58-3493250, Fax (+48)-58-3493257

Abstract – Synthesis of novel 5-methylidene-1,2,3,5-tetrahydro[2,1-*b*]-quinazoline derivatives **2-4** with potential biological activities mediated by α-adrenergic and/or imidazoline receptors was performed by reacting 2-chloro-4,5-dihydroimidazole (**1**) with the corresponding 2-aminoacetophenones. Compound **2**, which incorporates an enamine moiety, underwent a 1,3-dipolar cycloaddition reaction with the appropriate nitrones **5-9** to give 1,2,3,5-tetrahydro-imidazo[2,1-*b*]quinazolin-5,5'-spiro-2',3'-diphenylisoxazol-idines **10-14**. Reactions of the title compounds **2** and **4** with dimethyl acetylene-dicarboxylate (DMAD) afforded dimethyl 2-(2,3-dihydroimidazo[2,1-*b*]quinazolin-5(1*H*)-ylidenemethyl)but-2-enedioates **15**, **16**. Imidazo[2,1-*b*]quinazoline **2** was further treated with acetyl chloride, benzoyl chloride and mesyl chloride to give the 1-substituted derivatives **17**, **18** and **19**, respectively. The structures of all new compounds obtained were confirmed by elemental analysis and spectral data (IR, ^{1}H- and ^{13}C-NMR) as well as X-ray crystallographic analysis of **3** and **18**.

Keywords: 5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines, 1,3-dipolar cycloaddition, alkylation, acylation, X-ray structure analysis.

Introduction

The well known aryliminoimidazolidines such as *clonidine* and *moxonidine* exhibit antihypertensive activity mediated by α-adrenergic and/or imidazoline receptors [1,2]. These compounds possess several rotational degrees of freedom and, therefore, offer opportunities for preparation of restricted analogs.

Previously, it was found that interconnecting the imidazoline and phenyl ring, as achieved in 2,3-dihydroimidazo[1,2-*a*]benzimidazole (**A**) or 1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazoline (**B**) (Figure 1), afforded agents capable of lowering the blood pressure of experimental animals [3, 4]. On the other hand, we have recently found that certain 2,3,5,6-tetrahydroimidazo[2,1-*b*][1,3,5]benzotriazepines of type **C** exhibit vasocontractile activity in isolated rabbit aortic rings, which is mediated by K_{ATP}-dependant channels [5]. The present study was aimed at synthesis, structural elucidation and reactivity of novel 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines, depicted in Figure 1 as **D**.

Figure 1.

Results and Discussion

As outlined in Scheme 1, the title 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines **2** and **4** were obtained by reacting equimolar amounts of 2-chloro-4,5-dihydroimidazole (**1**) with the appropriate 2-aminoacetophenone in dichloromethane at ambient temperature. The reaction apparently proceeds *via* the intermediacy of the formed cyclic hemiaminal of type **E**, which loses a water molecule with the formation of an enamine moiety. However, when compound **1** (1 equiv) was treated with 2-aminoacetophenone (0.5 equiv) the reaction led to the formation of a mixture of two products which could be separated by fractional crystallization to afford 1-(4,5-dihydroimidazol-2-yl)-5-methy-lidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (**3**) and the expected compound **2** (Scheme 1).

The structures of the compounds **2**, **3** and **4** were confirmed by elemental analyses as well as IR and NMR spectroscopic data. For example, the ^{1}H NMR spectrum of **2** showed a multiplet in the range of δ 3.59-3.68 originating from CH_2-CH_2 grouping of the imidazoline ring. Two distinct singlets at δ 3.71 and δ 4.51 were assigned to the nonequivalent olefinic Cβ-H protons.

Scheme 1.

(i) 2-Amino-4-R^1-5-R^2-acetophenone / CH_2Cl_2 / r.t.; (ii) 10% NaOH / H_2O; (iv) fractional crystallization.

The fusion of the two ring systems was confirmed by the presence in the ^{13}C-NMR spectrum of two signals at δ 140.17 and δ 154.11, attributable to the C-5 and C=N carbon atoms of the imidazoquinazoline moiety, respectively. On the other hand, a characteristic feature of the ^{1}H-NMR spectrum of the 1-substituted derivative **3** is the presence of two distinct multiplets in the range of δ 3.66-3.71 and δ 4.07-4.09 integrating to six and two protons, respectively, attributable to the two CH_2-CH_2 groupings of the imidazoline rings. In ^{13}C-NMR spectrum, two broad carbon resonances were observed at δ 45.66 and δ 50.92, attributable to C-4′ and C-5′ of the 2-substituted imidazoline ring, and a signal at δ 148.75, which in the HSQC (heteronuclear single quantum coherence) spectrum did not correlate to any ^{1}H resonances. Analysis of the long-range ^{1}H-^{13}C coupling pattern obtained from the HMBC (heteronuclear multiple bond coherence) experiment allowed us to assign this signal to the C-2′ carbon atom of the imidazoline ring. The structure of **3** was then confirmed unambiguously by X-ray crystallographic analysis (Figure 2).

Figure 2. ORTEP drawing showing the asymmetric part of the unit cell of **3** and atom labelling. Hydrogen bonds are shown with dashed lines. Displacement ellipsoids are drawn at 50% probability level.

The condensed tricyclic system of **3** is virtually planar with the imidazoline substituent aproximately in its plane. This conformation is stabilized by an intramolecular hydrogen bond N18-H···N1 (H18A···N1A 2.10 Å, <N18A-H18A···N1A 126º; H18A···N1A 2.08 Å, <N18A-H18A···N1A 126º). Whereas bonds C2-N1 and C14-N15 show considerable double-bond character [1.287(3) and 1.277(3) Å, respectively, for the molecule A; 1.280(3) and 1.277(3) Å, respectively, for the molecule B], the bonds C9-N1, C4-N3, N3-C2, C2-N11, N11-C14 and C14-N18 [bond lengths 1.337(3)-1.400(3) Å] are intermediate between single and double bonds. The C4-C18 bond of 1.334(3) Å is longer than the double bond in a disubstituted vinyl group (1.321 Å) [6] indicating that it is conjugated with the guanidine fragment and the benzene ring. The nitrogen atoms N3 and N11 show sp^2 hybridization, the maximum displacement of the N atom from the plane of its substituents being 0.037 Å.

Scheme 2.

Compd	R^3
5, 10	H
6, 11	4-CH$_3$
7, 12	4-Cl
8, 13	3-Cl
9, 14	4-OCH$_3$

15: R^1 = R^2 = H
16: R^1 = R^2 = OCH$_3$

(i) THF / 7h / reflux; (ii) DMAD / CH$_3$OH / rt.

Enamines are known to act as 1,3-dipolarophiles [8,9] and the 1,3-dipolar cycloaddition of nitrones to enamines resulting in the formation of isoxazolidine derivatives is well established [10-12]. Thus, the 1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazoline **2** was subjected to the reaction with nitrones. Upon treatment of **2** with an excess of the appropriate *N*-(benzylidene)aniline *N*-oxide **5-9** in anhydrous THF under reflux, the desired 1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolin-5,5′-spiro-2′-phenyl-3′-(3″- or 4″-R^3-phenyl)isoxazolidines **10-14** were obtained (Scheme 2). For the structural analysis of the compounds **10-14** a complete assignment of all protons was made using HSQC and HMBC spectra. For example, in the ^{1}H-NMR spectrum of **10** the AMX system was observed due to CH$_2$-CH grouping of the isoxazoline ring formed: δ 3.03 (dd, 1H, part A of AMX system, $J_{A,M}$ = 13.67 Hz, $J_{A,X}$ = 10.25 Hz); δ 3.42 – 3.47 (dd, 1H, part M of AMX system); δ 4.88, dd, 1H, part X of AMX system, J_{AX} = 10.25 Hz, J_{MX} = 8.18 Hz). In the HMBC spectrum the protons C4'-H correlated to the carbon resonances at δ 71.93 (C3′) and δ 91.11 (C5-O) and the C3′-H resonance showed a long-range correlation to the carbon signal at δ 51.46 (C4′). Hence, the results of NMR experiments supported the presence of 5,5'-spiro-isoxazolidine ring.

Next, we examined the reaction of 1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines **2** and **4** with dimethyl acetylenedicarboxylate (DMAD). It is well known, that the reactions of enamines with DMAD, depending on solvent and temperature, afford either the cycloaddition [13, 14] or Michael addition [13, 15] products. To identify reactive sites both at the alkene and nitrogen atom incorporated into guanidine moiety, the electronic structure of **2** was studied using *ab initio* 6-31G** calculations [7]. Reactive sites will correspond to regions where either the highest-occupied molecular orbital (orbital-controlled reactions) or negative charge (electrostatically-controlled reactions) is large. As shown in Scheme 1, the imidazoquinazoline **2** can exist in two possible tautomeric forms, the N1-H tautomer (**2**) or the N10-H tautomer (**2A**). Calculations of the corresponding energies indicate that **2** is more stable than **2A** by 5.1 kcal/mol (Figure 3).

Figure 3. Calculated [7] natural charges (plain), charges from Mulliken population analysis (italic) and atomic charges from electrostatic potential (underlined) for selected atoms of **2** and **2A**.

Figure 4. Absolute values of HOMO (left) and electrostatic potential (right) mapped in color [7] onto the surface of electron density of **2**.

The magnitudes of the calculated charges at N1, N4 and N10 suggest that the electrostatically-controlled reactions of **2** and **2A** should give rise to the formation of either the N10- or N1-substituted products. On the other hand, the HOMO (0.0190 a.u.) have the highest contribution for Cβ carbon atom of enamine moiety which should be involved in the orbital-controlled reactions with electrophiles (Figure 4). Treatment of **2** and **4** with DMAD in methanol at room temperature gave rise to the formation of the Michael addition products dimethyl 2-(2,3-dihydroimidazo[2,1-*b*]quinazolin-5(1*H*)-ylidenemethyl)but-2-enedioates (**15** and **16**) (Scheme 2). Apparently, the orbital-controlled reaction took place exclusively since no *N*-alkenylation was observed. In the ^{1}H- and ^{13}C-NMR spectra of **15** the presence of two methoxycarbonyl groups was confirmed by the resonances at δ$_H$ 3.37 and 3.76 (OC$\underline{H}_3$ groups) and δ$_C$ 51.64 and 52.70 (OC$\underline{H}_3$ groups), as well as δ$_C$ 167.41 and 168.77 ($\underline{C}$=O groups). The N1-H proton appeared as a broad singlet at δ 7.58 ppm.

Scheme 3.

17: R = CH$_3$
18: R = C$_6$H$_5$

(i) DMAD / CH$_3$OH / rt;
(ii) MsCl / pyridine / 0 ºC – rt.

19 (*Z*)   19 (*E*)

Compound **2** was then subjected to reaction with electrophilic acetyl chloride and benzoyl chloride in pyridine at ambient temperature to afford the corresponding N1-substituted enaminones **17** and **18**, respectively (Scheme 3). It is well known that enaminones can exist in the four possible conformations depicted in Figure 5 due to restricted rotation around the C=C double and the C–C=O single bonds [16-22].

Figure 5.

Analysis of the ^{1}H-NMR spectra of compound **17** run in CDCl$_3$ revealed doubled signals indicating the presence of a mixture of *ZZ* and *EZ* isomers (Figure 6). The olefinic Cβ-H proton appears at δ 5.22 for **17** (*EZ*), and at δ 6.13 for **17** (*ZZ*). Deshielding of the olefinic proton of *ZZ* isomer results from its relative proximity to the benzene ring. Furthermore, the aromatic proton C6-H of the *EZ* isomer (δ 9.03) is downfield of that of the *ZZ* isomer (δ 7.84) by 1.19 ppm, while signals of other protons are not duplicated.

Figure 6.

17 (ZZ)

E = - 889.87009960 a.u.
dipole moment = 2.89 Debye

Δ E = 1.1 kcal / mol

17 (EZ)

E = - 889.8683975 a.u.
dipole moment = 7.54 Debye

F

As shown in Figure 6, the ROESY spectrum of **17** displayed intense NOE cross peaks between the resonances of Cβ-H and both CH$_3$ and C6-H for *ZZ* isomer, whereas for isomer *EZ* the corresponding NOE effect was observed between Cβ-H and CH$_3$ group only. Based on the relative intensities of signals observed in ^{1}H NMR spectrum we conclude that in CDCl$_3$ the compound **17** exists in form of a mixture of two isomers *ZZ* and *EZ* in ratio 3.3 : 1.

Quantum chemical calculations [7] indicate that the *EZ* and *ZZ* isomers of **17** differ in energy by only 1.1 kcal/mol. Based upon their calculated dipole moments, *EZ* (μ = 7.54 D) would be predicted to predominate over *ZZ* (μ = 2.89 D) in polar solvents. Indeed, an inspection of the ^{1}H NMR spectrum of **17** run in DMSO-d$_6$ revealed a change of the *ZZ/EZ* isomer ratio to 1 : 1.1 (see Experimental section). Hence, these data postulate that the isomerism observed is due to a restricted rotation around the C=C double bond and the interconversion between *ZZ* and *EZ* isomers is possible *via* a zwitterionic intermediate of type **F** (Figure 6).

It should be pointed out that 2-(1-benzoyl-2,3-dihydroimidazo[2,1-*b*]quinazolin-5(1*H*)-ylidene)-1-phenyl-ethen-1-one (**18**) exists both in solution and solid phase as a single *ZZ* isomer, which was confirmed by NMR spectroscopy and X-ray crystallographic analysis (Figure 7).

Figure 7. ORTEP drawing of molecule **18** with atom labelling. Displacement ellipsoids were draw at 50% probability level.

The tricyclic system of **18** is less planar than in **3** (cf. Figure 2) due to the steric hindrance caused by introduction of the benzoyl substituent at C14. The release of this strain is accomplished by a twist about the formally double C4-C14 and partially double C14-C15 bonds by 21.6º and 31.3º, respectively. In effect the carbonyl O16 is at a distance of 2.24 Å from one of the imidazolidine C13 hydrogen atoms, i.e. at a distance ca. 0.4 Å shorter than the sum of appropriate van der Waals radii [23]. The formally double bond C4-C14 which is conjugated not only with the quinazoline moiety like in **3** but also with the benzoyl group is significantly longer and equals to 1.367(3) Å. The tertiary

amide group is strongly non-planar with atoms C12 and C2 deviating from the plane of C25, C23, O24 and N11 by –0.224 and 0.539 Å, respectively. Contrary to **3**, the nitrogen atoms N3 and N11 show hybridization intermediate between sp^2 and sp^3 with the displacement of the N atoms from the plane of their substituents equal to 0.099 and 0.146 Å, respectively.

Finally, we have also performed the reaction of **2** with methanesulfonyl chloride (MsCl). The reaction proceeded smoothly in pyridine at ambient temperature and furnished 1-mesyl derivative **19** (Scheme 3), which, as evidenced by its ^{1}H-NMR spectrum run in DMSO-d_6, exists as a mixture of *ZZ* and *EE* isomers in a 1 : 9 ratio, respectively.

Conclusions

We have found that 2-chloro-4,5-dihydroimidazole (**1**) reacts with 2-aminoacetophenones to give tricyclic 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazolines (**2-4**) with potential circulatory activity. These compounds undergo facile reactions characteristic of enamine functionality such as 1,3-dipolar cycloaddition, Michael addition and electrophilic alkenylation at the Cβ carbon atom and/or N1 nitrogen atom.

Acknowledgements

Experimental

General

Melting points (mp) were determined on a Büchi 535 apparatus and are uncorrected. IR spectra (KBr pellets) were measured on a Perkin Elmer 1600 FTIR spectrophotometer. ^{1}H-NMR and ^{13}C-NMR were recorded on a Varian Gemini 200 or Varian Unity 500 spectrometer and chemical shifts (δ) are expressed in ppm relative to internal tetramethylsilane. 2D NMR experiments were carried out on a Varian Unity Plus 500 spectrometer. Mass spectra were recorded on a Finnigan MAT 95 spectrometer at 70 eV. The starting 2-chloro-4,5-dihydroimidazole (**1**) and *N*-oxides *N*-(3- or 4-R^3-benzylidene)aniline (**5-9**) were prepared according to procedures described previously [24, 25].

5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (**2**) *and 1-(4,5-Dihydro-1H-imidazol-2-yl)-5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline hydrate* (**3**).

2-Aminoacetophenone (1.66 g, 12.3 mmol) was added to a solution of **1** (2.5 g, 24 mmol) in CH$_2$Cl$_2$ (30 mL) and the reaction mixture was stirred at ambient temperature for 17 h. The solid that

precipitated was collected by filtration, washed with CH_2Cl_2 (20 mL), dried and dissolved in water (25 mL). To the solution thus obtained 10% aqueous NaOH (10 mL, 25 mmol) was added and the resulting mixture was stirred for 30 min. The crude product (a mixture of **2** and **3**) was filtered off, washed with water (10 mL), dried and heated in toluene (1:5) under reflux for 5 min. Then, the insoluble material was separated from the filtrate (denoted as "**A**" and stored for further work up), washed with hot toluene (4 mL) and dried to give **2** (0.42 g, 18%). The; mp 194-197°C; IR (KBr) cm^{-1}: 3155, 3110, 3060, 3020, 2860, 1655, 1615, 1595, 1560, 1495, 1460, 1440, 1280; ^{1}H-NMR (200 MHz, DMSO-d$_6$) δ: 3.59-3.68 (m, 4H, 2CH$_2$), 3.71 (s, 1H, CH), 4.51 (s, 1H, CH), 6.86-6.90 (m, 2H, H-7, -9), 7.13-7.24 (m, 2H, H-8 and NH), 7.58 (d, $J_{6,7}$ = 7.4 Hz, 1H, H-6); ^{13}C-NMR (200 MHz, DMSO-d$_6$) δ: 39.75, 44.14, 75.60, 118.17, 121.09, 122.91, 123.54, 129.88, 140.17, 145.68, 154.11; Anal. Calcd. for C$_{11}$H$_{11}$N$_3$: C, 71.33; H, 5.98; N, 22.68; Found: C, 71.02; H, 5.69, N, 22.82.

The filtrate "A" was concentrated under reduced pressure. The precipitate thus obtained was collected by filtration and recrystallized from toluene to give **3** (0.43 g, 13%); mp 118-121°C; IR (KBr) cm^{-1}: 3320, 3290, 2935, 2860, 1655, 1615, 1600, 1505, 1485, 1460, 1435, 1340, 1280; ^{1}H-NMR (500 MHz, CDCl$_3$) δ: 3.66-3.71 (m, 6H, 3CH$_2$), 3.72 (d, J = 2.44 Hz, 1H, CH), 4.07-4.09 (m, 2H, CH$_2$), 4.55 (d, J = 2.44 Hz, 1H, CH), 7.02 (ddd, $J_{7,6}$ = 7.81 Hz, $J_{7,8}$ = 7.33 Hz, $J_{7,9}$ = 1.46 Hz, 1H, H-7), 7.08 (dd, $J_{9,8}$ = 8.30 Hz, $J_{9,7}$ = 1.46 Hz, 1H, H-9), 7.24-7.27 (m, 1H, H-8), 7.53 (dd, $J_{6,7}$ = 7.81 Hz, $J_{6,8}$ = 1.47 Hz, 1H, H-6), 7.73 (br s, 1H, NH); ^{13}C-NMR (500 MHz, CDCl$_3$) δ: 42.36, 42.72, 45.66, 50.92, 77.90, 119.28, 123.03, 124.10, 125.30, 130.57, 140.05, 142.96, 148.75, 157.60; Anal. Calcd. for C$_{14}$H$_{15}$N$_5$·H$_2$O: C, 61.98; H, 5.57; N, 25.81; Found: C, 61.72; H, 5.32, N, 25.64.

7,8-Dimethoxy-5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (**4**).

The reaction of **1** (2.5 g, 24 mmol) with 2-amino-4,5-dimethoxyacetophenone (2.40 g, 12.3 mmol) was carried out according to the procedure described above for **2** and **3**. The crude product obtained was recrystallized from dioxane to give **4** (0.8 g, 33%); mp 185-189°C; IR (KBr) cm^{-1}: 3170, 3115, 3075, 3010, 2880, 2835, 1655, 1625, 1615, 1510, 1490, 1450, 1420, 1270, 1225, 1210; ^{1}H-NMR (500 MHz, DMSO-d$_6$) δ: 3.50-3.53 (m, 2H, CH$_2$), 3.55 (s, 1H, CH), 3.60-3.64 (m, 2H, CH$_2$), 3.71 (s, 3H, OCH$_3$), 3.72 (s, 3H, OCH$_3$), 4.29 (s, 1H, CH), 6.41 (s, 1H, H-9), 6.88 (1H, br s, NH), 6.99 (1H, s, H-6); ^{13}C-NMR (500 MHz, DMSO-d$_6$) δ: 39.69, 44.83, 55.90, 56.60, 74.08, 106.45, 107.06, 110.57, 140.87, 141.12, 145.00, 151.59, 154.32; MS (70 eV) m/z: 245 (M+, 100%); Anal. Calcd. for C$_{13}$H$_{15}$N$_3$O$_2$: C, 63.67; H, 6.16, N, 17.13; Found: C, 63.35; H, 5.97, N, 17.01.

General Procedure for the Preparation of 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(3′′- or 4′′-R^3-phenyl)isoxazolidines (**10-14**).

A mixture of **2** (0.45 g, 2.4 mmol) and the appropriate *N*-(3- or 4-R^3-benzylidene)-aniline *N*-oxide (**5-9**) (5.3 mmol) in anhydrous THF (15 mL) was refluxed for 7 h, and then, the resulting solution was allowed to stand overnight before workup according to procedures A or B.

Procedure A: The precipitate thus obtained was separated by suction, washed successively with anhydrous THF (6 mL) and anhydrous acetone (10 mL) and dried to give the products **10** and **11**, respectively.

1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′,3′-diphenylisoxazolidine (**10**). Yield 50%; mp 173-174°C (dec.); IR (KBr): 3155, 3100, 3060, 2865, 2830, 1660, 1595, 1570, 1475, 1460, 1280 cm^{-1}; ^{1}H-NMR (500 MHz, DMSO-d$_6$) δ: 3.03 (dd, $J_{A,M}$ = 13.67 Hz, $J_{A,X}$ = 10.25 Hz, 1H, H$_A$-4′), 3.35-3.39 (m, 1H, CH$_2$), 3.42-3.47 (m, 1H, H$_M$-4′), 3.50-3.53 (m, 1H, CH$_2$), 4.09-4.23 (m, 2H, CH$_2$), 4.88 (dd, $J_{X,A}$ = 10.25 Hz, $J_{X,M}$ = 8.18 Hz, 1H, H$_X$-3′), 6.81-6.96 (m, 6H, Ar), 7.10-7.18 (m, 3H, Ar), 7.31-7.43 (m, 3H, 2H aromat. and NH), 7.56-7.61 (m, 3H, Ar); ^{13}C-NMR (500 MHz, DMSO-d$_6$) δ: 39.54, 44.62, 51.46, 71.93, 91.11, 117.09, 119.57, 121.18, 121.89, 122.74, 124.39, 127.16, 127.76, 127.91, 128.57, 129.02, 129.63, 129.81, 140.33, 146.01, 149.28, 156.67; Anal. Calcd. for C$_{24}$H$_{22}$N$_4$O: C, 75.37; H, 5.80; N, 14.65; Found: C, 75.18; H, 5.48; N, 14.19.

1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4″-methylphenyl-isoxazolidine (**11**). Yield 54%; mp172-173°C (dec.); IR (KBr): 3165, 3050, 3025, 2970, 2920, 2850, 1650, 1595, 1490, 1475, 1460, 1280 cm^{-1}; ^{1}H-NMR (200 MHz, DMSO-d$_6$) δ: 2.31 (s, 3H, CH$_3$), 3.01 (dd, $J_{A,M}$ = 13.56 Hz, $J_{A,X}$ = 10.34 Hz, 1H, H$_A$-4′), 3.43-3.63 (m, 3H, H$_M$-4′ and CH$_2$), 4.10-4.25 (m, 2H, CH$_2$), 4.83 (dd, $J_{X,A}$ = 10.34 Hz, $J_{X,M}$ = 8.52 Hz, 1H, H$_X$-3′), 6.80-7.01 (m, 6H, Ar), 7.12-7.23 (m, 5H, 4H Ar and NH), 7.48-7.59 (m, 3H, Ar); Anal. Calcd. for C$_{25}$H$_{23}$N$_4$O: C, 75.93; H, 5.86; N, 14.17; Found: C, 76.21; H, 6.11; N, 13.91.

Procedure B: The insoluble side products were filtered off and then the solvent was distilled off under reduced pressure. The residue was treated with anhydrous acetone (7 mL), and the precipitate thus obtained was collected by filtration, washed with acetone (5 mL) and dried to give the products **12–14**.

1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4″-chlorophenyl)isoxazolidine (**12**). Yield 58%; mp172-175°C (dec.); IR (KBr): 3160, 3100, 3030, 2870, 1660, 1595, 1570, 1490, 1480, 1460, 1280 cm^{-1}; ^{1}H-NMR (200 MHz, DMSO-d$_6$) δ: 3.01-3.09 (m, 1H, H-4′), 3.45-3.58 (m, 3H, H-4′ and CH$_2$), 4.11-4.25 (m, 2H, CH$_2$), 4.95-5.00 (m, 1H, H-3′), 6.79-7.23 (m, 9H, Ar), 7.53-7.67 (m, 5H, 4H Ar and NH); Anal. Calcd. for C$_{24}$H$_{21}$ClN$_4$O: C, 69.14; H, 5.08; N, 13.44; Found: C, 69.27; H, 4.92; N, 13.59.

1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(3″-chlorophenyl)isoxazolidine (**13**). Yield 67%; mp 158-161°C; IR (KBr): 3160, 3095, 3060, 3025, 2885, 2865, 1660, 1595, 1570, 1485, 1475, 1460, 1280 cm^{-1}; ^{1}H-NMR (200MHz, DMSO-d$_6$) δ: 3.04 (dd, $J_{A,M}$ = 13.56 Hz, $J_{A,X}$ = 10.34 Hz, 1H, H$_A$-4′), 3.29-3.56 (m, 3H, H$_M$-4′ and CH$_2$), 4.13-4.26 (m, 2H, CH$_2$), 5.00 (dd, J = 10.34 Hz, J = 9.52 Hz, 1H, H$_X$-3′), 6.79-7.01 (m, 5H, Ar), 7.12-7.23 (m, 3H, Ar), 7.39-7.64 (m, 5H, 4H Ar

and NH); Anal. Calcd. for $C_{24}H_{21}ClN_4O$: C, 69.14; H, 5.08; N, 13.44; Found: C, 68.96; H, 5.16; N, 13.62.

1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4″-methoxyphenyl)isoxazolidine (**14**). Yield 68%; mp 158-160°C (dec.); IR (KBr): 3160, 3100, 3030, 2880, 2830, 1650, 1595, 1570, 1510, 1490, 1460, 1285, 1250 cm⁻¹; ¹H-NMR (200 MHz, DMSO-d₆) δ: 3.04-3.12 (m, 1H, H-4′), 3.40-3.53 (m, 3H, H-4′ and CH₂), 3.78 (s, 3H, OCH₃), 4.13-4.22 (m, 2H, CH₂), 4.78-4.87 (m, 1H, H-3′), 6.79-7.00 (m, 7H, Ar), 7.01-7.23 (m, 3H, Ar), 7.39 (s, 1H, NH), 7.50-7.66 (m, 3H, Ar); Anal. Calcd. for $C_{25}H_{24}N_4O_2$: C, 72.79; H, 5.86; N, 13.58; Found: C, 72.63; H, 6.11; N, 13.22.

General Procedure for the Preparation of Dimethyl 2-(7-R¹-8-R²-2,3-dihydroimidazo[2,1-b]-quinazol-ine-5(1H)-ylidenemethyl)but-2-enedioates (**15**, **16**).

To a suspension of the appropriate 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-*b*]quinazoline (**2** or **4**) (1.4 mmol) in anhydrous methanol (20 mL) DMAD (0.23 g, 1.6 mmoles) was added. The resulting mixture was stirred at room temperature for 15 h, and then the crude product (**15** or **16**) was separated by suction, washed with methanol (4 mL), dried and purified by crystallization from anhydrous methanol.

Dimethyl 2-(2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidenemethyl)but-2-enedioate (**15**). Yield 0.2 g (38%); mp 183-184°C; IR (KBr): 3170, 3115, 3020, 2880, 1715, 1700, 1665, 1600, 1580, 1460, 1250, 1180 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ: 3.37 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), 3.79-3.82 (m, CH₂), 3.99-4.03 (m, CH₂), 6.21 (s, 1H, HC=C), 6.29 (d, *J* = 1.47 Hz, 1H, HC-CO), 6.91-7.00 (m, 2H, H-7, -9), 7.25-7.31 (m, 2H, H-6, -8), 7.58 (br s, 1H, NH); ¹³C-NMR (500 MHz, CDCl₃) δ: 39.76, 45.76, 51.64, 52.70, 93.02, 118.54, 119.18, 121.95, 123.20, 128.09, 131.70, 143.67, 146.16, 146.84, 155.07, 167.41, 168.77; Anal. Calcd. for $C_{17}H_{17}N_3O_4$: C, 62.38; H, 5.23; N, 12.84; Found: C, 62.01; H, 5.17; N, 12.60.

Dimethyl 2-(7,8-dimethoxy-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidenemethyl)-but-2-ene-dioate (**16**). Yield 0.31 g (57%); mp 215-216°C (dec.); IR (KBr): 3165, 3110, 3040, 2945, 2890, 2840, 1725, 1700, 1660, 1615, 1565, 1440, 1260, 1210, 1180 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ: 3.43 (s, 3H, OCH₃), 3.73-3.81 (m, 5H, CH₂ and OCH₃), 3.84 (s, 3H, OCH₃), 3.90 (s, 3H, OCH₃), 4.01-4.09 (m, 2H, CH₂), 6.16 (s, 1H, HC=C), 6.24 (s, 1H, HC-CO), 6.60 (s, 1H, H-9), 6.77 (s, 1H, H-6); Anal. Calcd. for $C_{19}H_{21}N_3O_6$: C, 58.91; H, 5.46; N, 10.85; Found: C, 58.79; H, 5.28; N, 10.51.

1-(1-Acetyl-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidene)acetone (**17**).

To a suspension of **2** (0.53 g, 3 mmol) in pyridine (10 mL) acetyl chloride (0.71 g, 9 mmol) was added at 0 ºC. After an exothermic reaction had subsided (15 min), the reaction mixture was stirred at

rt for 6 h. Then, the precipitate was collected by filtration, dried, and treated with water (10 mL). The mixture thus obtained was made alkaline to pH 9 with 5% aqueous Na_2CO_3 and filtered off to give the crude product **17** as a mixture of two isomers (***ZZ/EZ***) which was purified by crystallization from DMF. Yield 0.43 g (56%); mp 202-205 °C; Anal. Calcd. for $C_{15}H_{15}N_3O_2$: C, 66.90; H, 5.61; N, 15.60; Found: C, 66.78; H, 5.42; N, 15.62; IR (KBr): 3060, 2920, 1680, 1645, 1635, 1600, 1560, 1520, 1480, 1470, 1410, 1380, 1230, 1150 cm^{-1}; ^{1}H-NMR (500 MHz, CDCl$_3$): ***ZZ/EZ*** isomer ratio 3.3:1, respectively: δ: 2.30 (s, 3H, OCH$_3$), 2.77 (s, 3H, OCH$_3$), 3.85-3.89 (m, 0.92H, CH$_2$CH$_2$ imidaz., ***EZ*** isomer), 4.07-4.20 (m, 3.08H, CH$_2$CH$_2$ imidaz., ***ZZ*** isomer), 5.22 (br s, 0.23H, CH, ***EZ*** isomer), 6.13 (s, 0.77H, CH, ***ZZ*** isomer), 7.22-7.40 (m, 2H, H-7, -9), 7.49-7.57 (m, 1H, H-8), 7.84 (s, 0.77H, H-6, ***ZZ*** isomer), 9.03 (br s, 0.23H, H-6, ***EZ*** isomer); ***ZZ/EZ*** isomer ratio 1:1.1, respectively: δ: 2.21 (s, 3H, OCH$_3$), 2.64 (s, 3H, OCH$_3$), 3.93-3.97 (m, 4H, CH$_2$CH$_2$ imidaz.), 5.38 (s, 0.52H, CH, ***EZ*** isomer), 6.30 (s, 0.48H, CH, ***ZZ*** isomer), 7.20-7.31 (m, 2H, H-7, -9), 7.56 (s, 1H, H-8), 8.05 (s, 0.47H, H-6, ***ZZ*** isomer), 9.11 (s, 0.53H, H-6, ***EZ*** isomer).

2-(1-Benzoyl-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidene)-1-phenylethen-1-one (**18**).

Benzoyl chloride (0.98 g, 7 mmol) was added at 0 ºC to a suspension of **2** (0.43 g, 2.3 mmol) in pyridine (10 mL). After the initial exothermic reaction had subsided (ca. 15 min), the reaction mixture was stirred at rt for 6 h, and then concentrated to dryness under reduced pressure. The residue was treated with 5% aqueous Na_2CO_3 and extracted with methylene chloride (100 mL). The organic phase was dried over $MgSO_4$ and then the solvent was evaporated under reduced pressure. The dry residue thus obtained was recrystallized from DMF to give **18** (0.42 g, 47%); mp 207-210°C; IR (KBr): 3060, 1666, 1645, 1620, 1595, 1530, 1470, 1400, 1315, 1220 cm^{-1}; ^{1}H-NMR (500 MHz, CDCl$_3$) δ: 4.24-4.29 (m, 4H, 2CH$_2$), 6.74 (br s, 1H, CH), 6.91 (d, *J* = 7.81 Hz, 1H, Ar), 7.21-7.24 (m, 1H, Ar), 7.40-7.58 (m, 7H, Ar), 7.71-8.04 (m, 5H, Ar); ^{13}C-NMR (500 MHz, CDCl$_3$) δ: 43.27, 46.90, 91.16, 119.07, 123.77, 125.71, 127.01, 127.58, 128.24, 128.35, 129.01, 131.61, 131.70, 132.68, 134.36, 140.33, 143.72, 146.89, 148.28, 169.37, 186.82; MS (70 eV) m/z 393.1 (M+ 100%); Anal. Calcd. for $C_{25}H_{19}N_3O_2$: C, 76.32; H, 4.87; N, 10.68; Found: C, 76.05; H, 4.61; N, 10.70.

1-Mesyl-5H-5-mesylomethylidene-2,3-dihydroimidazo[2,1-b]quinazoline (**19).**

To a suspension of **2** (1 g, 5.4 mmol) in pyridine (10 mL) MsCl (1.85 g, 16.2 mmol) was added at 0 ºC. After the exothermic reaction had subsided (15 min), the reaction mixture was stirred at rt for 72 h. Then, the precipitate was collected by filtration and treated with water (10 mL). The solution thus obtained was made alkaline to pH 9 with 5% aqueous Na_2CO_3 and the solid that precipitated was filtered off to give the crude product **19** as a mixture of two isomers (***Z/E***) in a ratio 1:9, which was purified by crystallization from methanol. Yield: 0.7 g (38%); mp 220-221°C (dec.); IR (KBr): 3010, 2920, 1640, 1600, 1565, 1540, 1480, 1420, 1350, 1280, 1260, 1160 cm^{-1}; ^{1}H-NMR (200 MHz, DMSO-d$_6$) δ: 3.17 (s, 3H, CH$_3$), 3.35 (s, 3H, CH$_3$), 3.90-4.08 (m, 3.6H, CH$_2$CH$_2$ imidaz., ***E*** isomer), 4.46-4.62

(m, 0.4H, CH$_2$CH$_2$ imidaz., **Z** isomer) 5.55 (s, 0.9H, CH, **E** isomer), 6.45 (s, 0.1H, CH, **Z** isomer), 7.32-7.60 (m, 3H, H-7, -8, -9), 7.98 (d, *J* = 5.35 Hz, 0.1H, H-6, **Z** isomer), 8.59 (d, J = 5.45 Hz, 0.9H, H-6, **E** isomer); Anal. Calcd. for C$_{13}$H$_{15}$N$_3$O$_4$S$_2$: C, 45.73; H, 4.40; N, 12.31; Found: C, 45.89; H, 4.26; N, 12.28.

X-Ray Structure Analysis of Compounds **3** *and* **18** [26].

Crystal data for C$_{14}$H$_{15}$N$_5$·H$_2$O (**3**): monoclinic, space group *P2$_1$/c*, a = 15.952(1), b = 4.995(1), c = 33.246(1) Å, *β* = 93.61(1), *V* = 2643.8(6) Å^3, *Z* = 8, d_χ = 1.363 g.cm^{-3}, *T* = 293 K. Data were collected for a crystal with dimensions 0.5 x 0.3 x 0.05 mm on a Kuma KM4 diffractometer using graphite monochromated Cu *K$_\alpha$* radiation. Final R indices for 3031 reflections with I>2σ(I) and 368 refined parameters are: R$_1$ = 0.0457, wR$_2$ = 0.1105 (R$_1$ = 0.0867, wR$_2$ = 0.1270 for all 2102 data).

Crystal data for C$_{25}$H$_{19}$N$_3$O$_2$ (**18**): orthorhombic, space group *Pna2$_1$*, a = 11.6591(11), b = 9.8033(9), c = 17.1225(16) Å, *V* = 1957.1(3) Å^3, *Z* = 4, d_χ = 1.335 g.cm^{-3}, *T* = 293 K. Data were collected for a crystal with dimensions 0.5 x 0.5 x 0.5 mm on a Kuma CCD diffractometer using graphite monochromated Mo *K$_\alpha$* radiation. Final R indices for 1879 reflections with I>2σ(I) and 291 refined parameters are: R$_1$ = 0.0376, wR$_2$ = 0.0927 (R$_1$ = 0.0432, wR$_2$ = 0.0969 for all 4437 data).

References and Notes

1. Ruffolo Jr., R.R.; Bondinell, W.; Hieble, J.P. *α*- and *β*-Adrenoceptors: From the Gene to the Clinic 2. Structure-Activity Relanstioships and Therapeutic Applications. *J. Med. Chem.* **1995**, *38*, 3683-3716.

2. Farsang, C.; Kapocsi, J. Imidazoline Receptors: From Discovery to Antihypertensive Therapy (facts and doubts). *Brain Res. Bull.* **1999**, *49*, 317-33.

3. Jen, T.; Bender, P.; Van Hoeven, H.; Dienel B.; Loev, B. Amidines 4. Synthesis of Tricyclic Guanidines Related to 1,2,3,5-Tetrahydroimidazo[2,1-*b*]quinazoline, a New Antihypertensive Agent. *J. Med. Chem.* **1973**, *16*, 407-408.

4. Jen, T.; Dienel B.; Bowman, H.; Petta, J.; Helt, A.; Loev, B. Amidines 2. A New Class of Antihypertensive Agents. 1,2,3,5-Tetrahydroimidazo[2,1-*b*]quinazolines. *J. Med. Chem.* **1972**, *15*, 727-731.

5. Sączewski, F.; Kobierska, E.; Petrusewicz, J.; Gendźwiłł, A.; Gdaniec, M. Sythesis and Structure of Novel 2,3,5,6-Tetrahydro-1*H*-imidazo[2,1-*b*][1,3,5]triazepines with Vasocontractile Activity in Rabbit Aortic Rings. *Il Farmaco* **2003**, *58*, 1171-1178.

6. Orpen, A.G.; L. Brammer, Allen, F.H.; Kennard, O.; Watson, D.G.; Taylor, R. In *Structure Correlation*; H.-B. Bürgi, J.D. Dunitz, Eds.; VCH Publishers, Inc.: New York, **1994**; *2*, 751.

7. Full geometry optimization, total energy calculations and obtaining the graphs that show the absolute values of the HOMO/LUMO and absolute values of the electrostatic potential on the

electron density isosurface corresponding van der Waals contact surface were performed using ab initio module (6-31G** basis set, direct Hartree-Fock method) as implemented in the SPARTAN program version 5.0, 1977 (Wavefunction Inc.), installed on a Silicon Graphics O2 workstation.

8. Kuehne, M.E.; Weaver, S.J.; Franz, P. Enamines as 1,3-Dipolarophiles. *J. Org. Chem*. **1964**, *29*, 1582-1585.

9. Munk, M.E.; Kim, Y.K. Enamines as Dipolarophiles in 1,3-Dipolar Addition Reactions. *J. Am. Chem. Soc*. **1964**, *86*, 2213-2217.

10. Tsuge, O.; Tashiro, M.; Nishihara, Y. Enamine Chemistry I. Dipolar Cycloaddition Reaction of Enamines with Nitrones. *Tetrahedron Lett*. **1967**, *38*, 3769-3774.

11. Nomura, Y.; Furusaki, F.; Takeuchi, Y. 1,3-Dipolar Cycloaddition of Diphenylnitrone to Enamines. *Bull. Chem. Soc. Jpn*. **1967**, *40*, 1740.

12. Nomura, Y.; Furusaki, F.; Takeuchi, Y. "Reverse-oriented" Cycloaddition of Nitrone to Enamine. *Bull. Chem. Soc. Jpn*. **1970**, *43*, 1913.

13. Brannock, K.C.; Burpitt, R.D.; Goodlett, V.W.; Thweatt, J.G. Enamine Chemistry. II. Reactions with Acetylenedicarboxylates. *J. Org. Chem.* **1963**, *28*, 1464-1468.

14. Verboom, W.; Visser G.W.; Trompenaars, W.P.; Reinhoudt, D.N.; Harkema, S.; Van Hummel, G.J. Sythesis of Pyrrolizines by Intramolecular Capture of 1,4-Dipolar Intermediates in Reactions of Enamines with Dimethyl Acetylenedicarboxylate. *Tetrahedron* **1981**, *37*, 3525-3533.

15. Menachery, M.D.; Saā, J.M.; Cava, M.P. Dehydroaporphines. Enamine-Type Michael Additions. *J. Org. Chem.* **1981**, 46, 2584-2588.

16. Kozerski, L.; Dąbrowski, J. Conformational Studies by Nuclear Magnetic Resonance –V. [13]C Spectra and Structural Problems of Enamino Carbonyl Compounds. *Org. Magn. Reson*. **1973**, *5*, 459-462.

17. Dąbrowski, J.; Kozerski, L. Conformational Studies by Nuclear Magnetic Resonance-VI. C-C and C-N Rotation Bariers in Various Enamine Derivatives. *Org. Magn. Reson*. **1973**, *5*, 469-470.

18. Dąbrowski, J.; Kamieńska-Trela, K.; Kozerski, L. Conformational Studies by Nuclear Magnetic Resonance. VII-The Direct Observation of Rotational Isomers in some Enamino Carbonyl Compounds and their Thione Derivatives by Carbon Magnetic Resonance. *Org. Magn. Reson*. **1974**, *6*, 499-502.

19. Dąbrowski, J.; K. Kamieńska-Trela, K. Electronic Spectra of α,β-Unsaturated Carbonyl Compounds. I. An Evaluation of Increments Characteristic of Changes in Configuration (cis / trans) and Conformation (s-cis / s-trans) Based on Direct Observation of the Isomerization of Enamino Aldehydes and Ketones. *J. Am. Chem. Soc*. **1976**, *98*, 2826-2834.

20. Kozerski, L.; Kamieńska-Trela, K.; Kania, L. ^{15}N-NMR Study of Activated Enamines. Structural Dependence of δ (^{15}N) and ^{n}J (N, H) in Primary, Secondary and Tertiary Enamino-Ketones, Esters and Amides. *Helv. Chim. Acta* **1983**, *66*, 2113-2128.

21. Vdovenko, S.I.; Gerus, I.I.; Gorbunova, M.G. *J.* α,β-Unsaturated Enamino-ketones with Trifluoromethyl Groups. Infrared Spectra and Structure. *J. Chem. Soc. Perkin. Trans. 2* **1993**, 559-562.

22. Zhuo, J.C. ^{17}O NMR Spectroscopic Study of Tertiary Enaminones. *Magn. Reson. Chem.* **1996**, *34*, 595-602.

23. Bondi, A. Van der Waals Volumes and Radii. *J. Phys. Chem.* **1964**, 68, 441-451.

24. Trani, A.; Bellasio, E. Synthesis of 2-Chloro-2-imidazoline and its Reactivity with Aromatic Amines, Phenols, and Thiophenols. *J. Heterocyl. Chem.* **1974**, *11*, 257-261.

25. Rundel,W. In Houben-Weil, *Methoden der Organischen Chemie* **1968**, *10/4*, 311.

26. CCDC 229413 (compound **3**) and 229414 (compound **18**) contain the supplementary crystallographic data for these compounds. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk).